Market Place
Sourcing Support
MBX Biosciences Awards Inducement Grant Under Nasdaq Listing Rule
03 Apr 2026 //
GLOBENEWSWIRE
MBX Biosciences To Participate In Upcoming Investor Conferences
11 Feb 2026 //
GLOBENEWSWIRE
MBX Biosciences To Present 2026 Outlook At J.P. Morgan Conference
11 Jan 2026 //
GLOBENEWSWIRE
MBX Biosciences To Present At J.P. Morgan Healthcare Conference
15 Dec 2025 //
GLOBENEWSWIRE
MBX Biosciences To Join 37th Piper Sandler Healthcare Conference
18 Nov 2025 //
GLOBENEWSWIRE
MBX Biosciences To Participate In November Investor Conferences
20 Oct 2025 //
GLOBENEWSWIRE
Mbx Biosciences Reports Canvuparatide Success In Phase 2 Trial
22 Sep 2025 //
GLOBENEWSWIRE
MBX Biosciences Announces Proposed Public Offering
22 Sep 2025 //
GLOBENEWSWIRE
MBX Biosciences to Share Ph 2 Topline Results of Canvuparatide
19 Sep 2025 //
GLOBENEWSWIRE
MBX Bio Names Andreas Moraitis SVP of Clinical Development
23 Jun 2025 //
GLOBENEWSWIRE
MBX Biosciences submits IND for long-acting obesity treatment.
16 Jun 2025 //
GLOBENEWSWIRE
MBX Biosciences to Present at ADA 85th Scientific Sessions
10 Jun 2025 //
GLOBENEWSWIRE
MBX Biosciences to Participate in June Investor Conferences
20 May 2025 //
GLOBENEWSWIRE
MBX Biosciences Reports Q1 2025 Financial Results and Highlights
12 May 2025 //
GLOBENEWSWIRE
MBX Biosciences Appoints Steve Hoerter to Board
07 Apr 2025 //
GLOBENEWSWIRE
MBX Biosciences Announces Additions to Leadership Team
05 Mar 2025 //
GLOBENEWSWIRE
MBX Bio Completes Enrollment In Ph2 Trial For Hypoparathyroidism
03 Mar 2025 //
GLOBENEWSWIRE
MBX Biosciences to Participate in March Investor Conferences
18 Feb 2025 //
GLOBENEWSWIRE
MBX Bio to Participate in Upcoming February Investor Conferences
23 Jan 2025 //
GLOBENEWSWIRE
MBX Bio to Participate in 43rd J.P. Morgan Healthcare Conference
18 Dec 2024 //
GLOBENEWSWIRE
MBX Bioscience Reports Q3 2024 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
MBX Biosciences to Attend November Investor Conferences
28 Oct 2024 //
#N/A
MBX Biosciences Closes Upsized Initial Public Offering
16 Sep 2024 //
GLOBENEWSWIRE
MBX Files For IPO To Fund Phase 3 Of Yorvipath Challenger
26 Aug 2024 //
FIERCE BIOTECH
MBX Biosciences Doses First Patient In Phase 2 Hypoparathyroidism Trial
12 Aug 2024 //
GLOBENEWSWIRE
MBX Biosciences Raises $63.5M In Series C Financing
05 Aug 2024 //
GLOBENEWSWIRE
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
25 Jun 2024 //
GLOBENEWSWIRE
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
31 Oct 2023 //
GLOBENEWSWIRE
MBX Bio to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
24 Jan 2023 //
GLOBENEWSWIRE
MBX Biosciences Closes $115 Million Series B Financing
14 Nov 2022 //
GLOBENEWSWIRE
MBX Biosciences Advances Ph1 Trial of Long-Acting Parathyroid , MBX 2109
05 Oct 2022 //
GLOBENEWSWIRE
MBX Biosciences Receives ODD for Lead Candidate MBX 2109 for Hypoparathyroidism
26 Jul 2022 //
GLOBENEWSWIRE
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
11 Apr 2022 //
GLOBENEWSWIRE
